The Emerging Burden of Liver Disease in Cystic Fibrosis Patients: A UK Nationwide Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Apr 5

PMID 30947265

Citations 17

Authors

M B Toledano

S K Mukherjee

J Howell

D Westaby

S A Khan

D Bilton

N J Simmonds

Affiliations

Soon will be listed here.

Abstract

Objective: Cystic fibrosis associated liver disease (CFLD) is the third largest cause of mortality in CF. Our aim was to define the burden of CFLD in the UK using national registry data and identify risk factors for progressive disease.

Methods: A longitudinal population-based cohort study was conducted. Cases were defined as all patients with CFLD identified from the UK CF Registry, 2008-2013 (n = 3417). Denominator data were derived from the entire UK CF Registry. The burden of CFLD was characterised. Regression analysis was undertaken to identify risk factors for cirrhosis and progression.

Results: Prevalence of CFLD increased from 203.4 to 228.3 per 1000 patients during 2008-2013. Mortality in CF patients with CFLD was more than double those without; cirrhotic patients had higher all-cause mortality (HR 1.54, 95% CI 1.09 to 2.18, p = 0.015). Median recorded age of cirrhosis diagnosis was 19 (range 5-53) years. Male sex, Pseudomonas airway infection and CF related diabetes were independent risk factors for cirrhosis. Ursodeoxycholic acid use was associated with prolonged survival in patients without cirrhosis.

Conclusions: This study highlights an important changing disease burden of CFLD. The prevalence is slowly increasing and, importantly, the disease is not just being diagnosed in childhood. Although the role of ursodeoxycholic acid remains controversial, this study identified a positive association with survival.

Citing Articles

Genetic engineering drives the breakthrough of pig models in liver disease research.

Xu C, Fang X, Xu X, Wei X Liver Res. 2025; 8(3):131-140.

PMID: 39957748 PMC: 11771255. DOI: 10.1016/j.livres.2024.09.003.

Combined Organ Transplantation in Patients with Advanced Liver Disease.

Zhang I, Lurje I, Lurje G, Knosalla C, Schoenrath F, Tacke F Semin Liver Dis. 2024; 44(3):369-382.

PMID: 39053507 PMC: 11449526. DOI: 10.1055/s-0044-1788674.

Liver magnetic resonance elastography and fat fraction in pediatric patients with cystic fibrosis versus healthy children.

Tan A, Demirtas D, Hizarcioglu-Gulsen H, Karakaya J, Isiyel E, Ozen H Pediatr Radiol. 2023; 54(2):250-259.

PMID: 38133654 DOI: 10.1007/s00247-023-05832-1.

Improving detection of cystic fibrosis related liver disease using liver fibrosis assessment tools.

Scott J, Jones A, Jokl E, Gordon-Walker T, Barry P, Hanley N Heliyon. 2023; 9(11):e21861.

PMID: 38053913 PMC: 10694159. DOI: 10.1016/j.heliyon.2023.e21861.

Cystic fibrosis screening, evaluation, and management of hepatobiliary disease consensus recommendations.

Sellers Z, Assis D, Paranjape S, Sathe M, Bodewes F, Bowen M Hepatology. 2023; 79(5):1220-1238.

PMID: 37934656 PMC: 11020118. DOI: 10.1097/HEP.0000000000000646.

References

Sokol R, Durie P . Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr. 1999; 28 Suppl 1:S1-13. DOI: 10.1097/00005176-199900001-00001. View

Wilschanski M, Rivlin J, Cohen S, Augarten A, Blau H, Aviram M . Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics. 1999; 103(1):52-7. DOI: 10.1542/peds.103.1.52. View

Schaible B, Taylor C, Schaffer K . Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps. Antimicrob Agents Chemother. 2012; 56(4):2114-8. PMC: 3318321. DOI: 10.1128/AAC.05574-11. View

Lamireau T, Monnereau S, Martin S, Marcotte J, Winnock M, Alvarez F . Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004; 41(6):920-5. DOI: 10.1016/j.jhep.2004.08.006. View

Bartlett J, Friedman K, Ling S, Pace R, Bell S, Bourke B . Genetic modifiers of liver disease in cystic fibrosis. JAMA. 2009; 302(10):1076-83. PMC: 3711243. DOI: 10.1001/jama.2009.1295. View

Ling S, Wilkinson J, Hollman A, McColl J, Evans T, Paton J . The evolution of liver disease in cystic fibrosis. Arch Dis Child. 1999; 81(2):129-32. PMC: 1718033. DOI: 10.1136/adc.81.2.129. View

Chryssostalis A, Hubert D, Coste J, Kanaan R, Burgel P, Desmazes-Dufeu N . Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. J Hepatol. 2011; 55(6):1377-82. DOI: 10.1016/j.jhep.2011.03.028. View

Baraldi O, Valentini C, Donati G, Comai G, Cuna V, Capelli I . Hepatorenal syndrome: Update on diagnosis and treatment. World J Nephrol. 2015; 4(5):511-20. PMC: 4635371. DOI: 10.5527/wjn.v4.i5.511. View

Bronte V, Brandau S, Chen S, Colombo M, Frey A, Greten T . Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016; 7:12150. PMC: 4935811. DOI: 10.1038/ncomms12150. View

10.

Dasarathy S, Merli M . Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016; 65(6):1232-1244. PMC: 5116259. DOI: 10.1016/j.jhep.2016.07.040. View

11.

Lindblad A, Glaumann H, Strandvik B . Natural history of liver disease in cystic fibrosis. Hepatology. 1999; 30(5):1151-8. DOI: 10.1002/hep.510300527. View

12.

Alvaro D, Alpini G, Onori P, Perego L, Svegliata Baroni G, Franchitto A . Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology. 2000; 119(6):1681-91. DOI: 10.1053/gast.2000.20184. View

13.

FitzSimmons S . The changing epidemiology of cystic fibrosis. J Pediatr. 1993; 122(1):1-9. DOI: 10.1016/s0022-3476(05)83478-x. View

14.

Ruiz-Del-Arbol L, Serradilla R . Cirrhotic cardiomyopathy. World J Gastroenterol. 2015; 21(41):11502-21. PMC: 4631957. DOI: 10.3748/wjg.v21.i41.11502. View

15.

Corbett K, Kelleher S, Rowland M, Daly L, Drumm B, Canny G . Cystic fibrosis-associated liver disease: a population-based study. J Pediatr. 2004; 145(3):327-32. DOI: 10.1016/j.jpeds.2004.05.051. View

16.

Rodriguez-Roisin R, Krowka M . Hepatopulmonary syndrome--a liver-induced lung vascular disorder. N Engl J Med. 2008; 358(22):2378-87. DOI: 10.1056/NEJMra0707185. View

17.

Boelle P, Debray D, Guillot L, Clement A, Corvol H . Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients. Hepatology. 2018; 69(4):1648-1656. PMC: 6519059. DOI: 10.1002/hep.30148. View

18.

Byrne C, Targher G . NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl):S47-64. DOI: 10.1016/j.jhep.2014.12.012. View

19.

Lurz E, Patel H, Frimpong R, Ricciuto A, Kehar M, Wales P . Sarcopenia in Children With End-Stage Liver Disease. J Pediatr Gastroenterol Nutr. 2018; 66(2):222-226. DOI: 10.1097/MPG.0000000000001792. View

20.

Stonebraker J, Ooi C, Pace R, Corvol H, Knowles M, Durie P . Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. Clin Gastroenterol Hepatol. 2016; 14(8):1207-1215.e3. PMC: 4955685. DOI: 10.1016/j.cgh.2016.03.041. View